Choroid plexus cancer
Drug research and approvals for choroid plexus cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 6 studies of choroid plexus cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial IntelligenceNCT06878469 · Not applicable · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Jan 27, 2025
- A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNCT06357377 · Phase 1 · Neonc Technologies, Inc. · starts Sep 8, 2026
- Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and…NCT05259605 · Not reported · European Organisation for Research and Treatment of Cancer - EORTC · starts Mar 21, 2023
- Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline…NCT04185038 · Phase 1 · Seattle Children's Hospital · starts Dec 11, 2019
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsNCT03911388 · Phase 1 · M.D. Anderson Cancer Center · starts Sep 12, 2019
- Familial Investigations of Childhood Cancer PredispositionNCT03050268 · Not reported · St. Jude Children's Research Hospital · starts Apr 6, 2017
Phase 3 10
- CarboplatinDNA inhibitor
- VincristineTubulin inhibitor
- CyclophosphamideDNA inhibitor
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- TemozolomideDNA inhibitor
- DactinomycinDNA inhibitor
- Leucovorin
How its trials ended
27 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 10 whose ending is known, 10% met their primary endpoint, 0% missed it and 90% stopped early.
- Completed, result not reported1348%
- Stopped: other or unclear519%
- Ongoing415%
- Stopped: enrollment or feasibility27%
- Met its primary endpoint14%
- Stopped: lack of efficacy14%
- Stopped: sponsor or business decision14%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA